For example, compared with patients treated with nivolumab alone, patients treated with nivolumab plus ipilimumab have an increased incidence and severity of myocarditis.[10] Some anti-vascular endothelial growth factor treatments induce cardiotoxicity and are also associated with an increased risk of thrombosis and coronary ischemia.[11]. This evidence concerns the gene VEGFA and myocarditis.